EGM
GALT icon

Engineers Gate Manager’s Galectin Therapeutics GALT Stock Holding History

Engineers Gate Manager’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18,739
Closed -$52.3K – 2368
2026
Q1 		$52.3K Buy
+18,739
New +$57K ﹤0.01% 2082
2025
Q1 		– Sell
-16,491
Closed -$21.3K – 2296
2024
Q4 		$21.3K Buy
+16,491
New +$39.5K ﹤0.01% 2155

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Engineers Gate Manager's GALT Position: Q2 2026 in Review

Engineers Gate Manager sold out of Galectin Therapeutics (GALT) in Q2 2026, closing a stake of 18,739 shares — an estimated $52.3K sold.

Engineers Gate Manager first reported a position in GALT in Q4 2024 and held it in 2 quarters. The position peaked at $52.3K in Q1 2026. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Engineers Gate Manager reported no remaining Galectin Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Engineers Gate Manager sold 18,739 Galectin Therapeutics shares in Q2 2026, an estimated $52.3K.
  • Engineers Gate Manager first reported a position in Galectin Therapeutics in Q4 2024 and held it in 2 quarters.
  • Engineers Gate Manager's Galectin Therapeutics position peaked at $52.3K in Q1 2026.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.